Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

The revelation of a patient death in Bristol Myers Squibb’s phase 3 trial of a potential pulmonary fibrosis treatment has ...

Novartis is paying Abogen Biosciences $575 million upfront for an mRNA-encoded T-cell engager (TCE) that showed early clinical promise in autoimmune disease. The deal, which inclu ...

Adecto Pharmaceuticals’ 12-year story has come to an end as the immunotherapy biotech blamed a “risk-averse funding environment” for shutting up shop. | Adecto Pharmaceuticals’ 12-year story has come ...

Sanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage im | Sanofi is paying Regeneron $1 billion ...

A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary ...

As Foghorn digested the end of the Lilly partnership, the biotech said it was laying off 40% of its workforce, while “further ...

Roche Diagnostics has launched a new in vitro diagnostic test for newborn screening to detect a series of rare disorders.  | Roche Diagnostics has launched a new in vitro diagnostic test for newborn ...

A more subdued volume of biopharma layoffs continued into the third quarter of 2026, validating predictions that the sector ...

Zealand Pharma has shared primary endpoint data on Roche-partnered petrelintide, revealing that the middle dose of the amylin ...

Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the ...

Merck touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis ...